Successful postexposure vaccination against hepatitis B in chimpanzees

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Hepatitis B virus (HBV) infection poses a significant global health risk.
• Postexposure prophylaxis for hepatitis B typically involves hepatitis B immune globulin (HBIG) and vaccination.
• The efficacy of postexposure vaccination alone, especially with accelerated schedules, requires further investigation.

Purpose of the Study:

• To evaluate the effectiveness of postexposure hepatitis B (HB) vaccination without HBIG.
• To determine the optimal timing for initiating postexposure HB vaccination after HBV exposure.
• To assess the impact of accelerated vaccination schedules on HBV infection outcomes.

Main Methods:

• Four chimpanzees received intravenous HBV inoculum.
• Vaccination with HB vaccine was administered at 4, 8, 48, and 72 hours post-exposure.
• Accelerated vaccination schedules (2 and 6 weeks) were used, shorter than standard recommendations.
• Animals were monitored for 1 year for HBs-antigenemia, ALT levels, and liver histology.
• One unvaccinated chimpanzee served as a control.

Main Results:

• None of the vaccinated chimpanzees developed HBs-antigenemia, elevated ALT, or liver damage.
• A late appearance of anti-HBc was noted only in the animal vaccinated 72 hours post-exposure.
• The unvaccinated control developed clinical hepatitis B within 2 months.

Conclusions:

• Postexposure hepatitis B vaccination initiated within 48 hours of HBV exposure can prevent infection.
• Accelerated vaccination schedules are effective, even without concomitant HBIG administration.
• Early postexposure vaccination is a viable strategy for hepatitis B prevention.